Childhood Cancers

Treatment with tovorafenib led to a 64% overall response rate in patients with recurrent or progressive pediatric low-grade glioma, study findings showed.

There were some monumental FDA approvals in the cancer space during 2022 — here’s a roundup of our most-read agency decisions of the year.

A childhood cancer survivor now works raising funds for Children’s Hospital of Philadelphia, the same hospital where she received treatment for Ewing sarcoma at 12 years old.

From Tina Turner’s son, Ronnie, dying of cancer to the Miami Dolphins honoring a group of people who raised over $5 million for oncology care and research, here is what’s happening in the cancer space this week.

The treatment and support that children with cancer receive has advanced over the past 20 years, but more progress to improve the cure rate is on the horizon.

Tecentriq was approved by the FDA for adults and children aged two years and older with advanced alveolar soft part sarcoma, a disease typically diagnosed in approximately 80 patients per year in the U.S.

Children with acute lymphoblastic leukemia had a 2.4-fold greater risk of relapse if they were considered extremely obese while undergoing maintenance therapy.

A nurse shares what it was like when her daughter was diagnosed with an aggressive cancer during the beginning of the COVID-19 pandemic.

Childhood cancer survivors who had high daily sugar intake — especially when it came to sweetened beverages — had an increased risk of premature aging-related health complications, according to recent research.

Though remission rates for children who underwent CAR-T cell therapy did not differ based on socioeconomic status, accessibility gaps remain.

The Food and Drug Administration approved Adcetris plus chemotherapy for pediatric patients with classical high-risk Hodgkin lymphoma.

Members of the FDA’s Oncologic Drug Advisory Committee voted that there was insufficient evidence claiming that omburtamab improved survival in patients with neuroblastoma with central nervous system/leptomeningeal metastases.

From a childhood cancer survivor throwing out the first pitch at Game 4 of the World Series to former WWE champion and actor Dwayne “The Rock” Johnson recording a message for a child with brain cancer, here’s what’s happening in the cancer space this week.

Childhood cancer survivors should be aware of any symptoms they experience during survivorship and communicate those with their care team.

The use of a multi-agent chemotherapy regimen resulted in improved outcomes in a group of children with pleuropulmonary blastoma, a rare form of lung cancer, when compared with other regimens.

Ten years after being diagnosed with cancer, 11-year-old, 3-time neuroblastoma survivor Micah Bernstein and her father, Jeff, discuss how childhood cancer has changed over the past decade.

The Food and Drug Administration approved Pedmark for the prevention of chemotherapy-induced hearing loss in pediatric patients with localized, nonmetastatic solid cancers.

In honor of Childhood Cancer Awareness Month in September, CURE® compiled a roundup of some of the top stories involving the latest updates in the pediatric cancer space that patients and their families may have missed.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

It is important for cancer survivors to know their risk of developing heart disease, even years after treatment has ended, as they may be underdiagnosed or undertreated for them.

The FDA approved Imbruvica for children over the age of 1 who are experiencing chronic GVHD that has already been treated by one or more prior therapy.

Survivors of childhood cancer had higher rates of infection-related hospitalizations than their healthy peers, at both the five- and 10-year post-treatment mark.

From Dick Vitale receiving the Jimmy V Award at the 2022 ESPYs to a former triathlon champion opening up about his cancer experience, here’s what’s happening in the cancer space this week.

A first-in-human trial is investigating the safety and efficacy of the novel CAR-T cell therapy in patients relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Findings from several studies have shown that childhood cancer survivors often stop attending much needed follow-up visits in the years following treatment.